XML 53 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaboration and License Agreements (Tables)
 12 Months Ended
Dec. 31, 2013
Summary of Revenue from Collaboration and License Agreements

We have recognized revenue from our collaboration and license agreements as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2013

 

 

2012

 

 

2011

 

Novartis:

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of upfront license fee

 

$

-

 

 

$

53,846

 

 

$

7,692

 

Reimbursement of research and development expense

 

 

-

 

 

 

16,238

 

 

 

1,879

 

Novartis total

 

 

-

 

 

 

70,084

 

 

 

9,571

 

Merck:

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of upfront license fee

 

 

 

 

 

 

-

 

 

 

21,429

 

Reimbursement of research and development expense

 

 

-

 

 

 

-

 

 

 

9,973

 

Merck total

 

 

-

 

 

 

-

 

 

 

31,402

 

Biogen Idec:

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of upfront license fee

 

 

-

 

 

 

-

 

 

 

37,056

 

Biogen Idec total

 

 

-

 

 

 

-

 

 

 

37,056

 

BMS and Pfizer:

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of research and development services

 

 

4,042

 

 

 

1,958

 

 

 

-

 

BMS and Pfizer total

 

 

4,042

 

 

 

1,958

 

 

 

-

 

Bayer and Janssen:

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of research and development services

 

 

3,876

 

 

 

-

 

 

 

-

 

Bayer and Janssen total

 

 

3,876

 

 

 

-

 

 

 

-

 

Lee’s:

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of research and development services

 

 

194

 

 

 

-

 

 

 

-

 

Lee’s total

 

 

194

 

 

 

-

 

 

 

-

 

Daiichi Sankyo:

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of research and development services

 

 

2,419

 

 

 

 

 

 

 

 

 

Daiichi Sankyo total

 

 

2,419

 

 

 

-

 

 

 

-

 

Total collaboration and license revenue

 

$

10,531

 

 

$

72,042

 

 

$

78,029